{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:06:08Z","timestamp":1790175968854,"version":"4.1.0"},"reference-count":28,"publisher":"American Association for Cancer Research (AACR)","issue":"1","funder":[{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute (NCI)","doi-asserted-by":"publisher","award":["R01\tCA223231"],"award-info":[{"award-number":["R01\tCA223231"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute (NCI)","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute (NCI)","doi-asserted-by":"publisher","award":["R01 CA195476"],"award-info":[{"award-number":["R01 CA195476"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000070","name":"HHS | NIH | National Institute of Biomedical Imaging and Bioengineering (NIBIB)","doi-asserted-by":"publisher","award":["R00 EB014328"],"award-info":[{"award-number":["R00 EB014328"]}],"id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute (NCI)","doi-asserted-by":"publisher","award":["R21 CA212958"],"award-info":[{"award-number":["R21 CA212958"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute (NCI)","doi-asserted-by":"publisher","award":["K99 CA226357"],"award-info":[{"award-number":["K99 CA226357"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title\/>\n                  <jats:p>The ever-changing tumor microenvironment constantly challenges individual cancer cells to balance supply and demand, presenting tumor vulnerabilities and therapeutic opportunities. Everolimus and temsirolimus are inhibitors of mTOR (mTORi) approved for treating metastatic renal cell carcinoma (mRCC). However, treatment outcome varies greatly among patients. Accordingly, administration of mTORi in mRCC is diminishing, which could potentially result in missing timely delivery of effective treatment for select patients. Here, we implemented a clinically applicable, integrated platform encompassing a single dose of [1-13C] pyruvate to visualize the in vivo effect of mTORi on the conversion of pyruvate to lactate using hyperpolarized MRI. A striking difference that predicts treatment benefit was demonstrated using two preclinical models derived from patients with clear cell RCC (ccRCC) who exhibited primary resistance to VEGFRi and quickly succumbed to their diseases within 6 months after the diagnosis of metastasis without receiving mTORi. Our findings suggest that hyperpolarized MRI could be further developed to personalize kidney cancer treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Significance:<\/jats:title>\n                  <jats:p>These findings demonstrate hyperpolarized [1-13C]pyruvate MRI as a tool for accurately assessing the clinical success of mTOR inhibition in patients with ccRCC.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1158\/0008-5472.can-18-2231","type":"journal-article","created":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T17:13:43Z","timestamp":1542734023000},"page":"242-250","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Hyperpolarized MRI Visualizes Warburg Effects and Predicts Treatment Response to mTOR Inhibitors in Patient-Derived ccRCC Xenograft Models"],"prefix":"10.1158","volume":"79","author":[{"given":"Yiyu","family":"Dong","sequence":"first","affiliation":[{"name":"1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roozbeh","family":"Eskandari","sequence":"additional","affiliation":[{"name":"2Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"3Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Ray","sequence":"additional","affiliation":[{"name":"1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2105-4716","authenticated-orcid":false,"given":"Kristin L.","family":"Granlund","sequence":"additional","affiliation":[{"name":"2Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"3Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia Dos","family":"Santos-Cunha","sequence":"additional","affiliation":[{"name":"2Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"3Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesselin Z.","family":"Miloushev","sequence":"additional","affiliation":[{"name":"2Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"3Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sui Seng","family":"Tee","sequence":"additional","affiliation":[{"name":"2Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"3Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangmoo","family":"Jeong","sequence":"additional","affiliation":[{"name":"2Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"3Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Aras","sequence":"additional","affiliation":[{"name":"2Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5207-3648","authenticated-orcid":false,"given":"Ying-Bei","family":"Chen","sequence":"additional","affiliation":[{"name":"4Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily H.","family":"Cheng","sequence":"additional","affiliation":[{"name":"1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"4Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3595-0551","authenticated-orcid":false,"given":"James J.","family":"Hsieh","sequence":"additional","affiliation":[{"name":"5Molecular Oncology, Department of Medicine, Siteman Cancer Center, Washington University, St. Louis, Missouri."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayvan R.","family":"Keshari","sequence":"additional","affiliation":[{"name":"2Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"3Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"6Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2019,1,2]]},"reference":[{"key":"2022061706341150600_bib1","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"key":"2022061706341150600_bib2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","article-title":"Targeting the PI3K pathway in cancer: are we making headway?","volume":"15","author":"Janku","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2022061706341150600_bib3","doi-asserted-by":"crossref","first-page":"33085","DOI":"10.1074\/jbc.274.46.33085","article-title":"Opposite translational control of GLUT1 and GLUT4 glucose transporter mRNAs in response to insulin - Role of mammalian target of rapamycin, protein kinase B, and phosphatidylinositol 3-kinase in GLUT1 mRNA translation","volume":"274","author":"Taha","year":"1999","journal-title":"J Biol Chem"},{"key":"2022061706341150600_bib4","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006070","article-title":"Metabolic imaging of patients with prostate cancer using hyperpolarized [1-C-13]Pyruvate","volume":"5","author":"Nelson","year":"2013","journal-title":"Sci Transl Med"},{"key":"2022061706341150600_bib5","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1158\/0008-5472.CAN-18-0221","article-title":"Metabolic imaging of the human brain with hyperpolarized 13C pyruvate demonstrates 13C lactate production in brain tumor patients","volume":"78","author":"Miloushev","year":"2018","journal-title":"Cancer Res"},{"key":"2022061706341150600_bib6","doi-asserted-by":"crossref","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2022061706341150600_bib7","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1158\/1078-0432.CCR-13-2345","article-title":"Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy","volume":"20","author":"Voss","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2022061706341150600_bib8","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/nrurol.2015.260","article-title":"A river model to map convergent cancer evolution and guide therapy in RCC","volume":"12","author":"Wei","year":"2015","journal-title":"Nat Rev Urol"},{"key":"2022061706341150600_bib9","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.euf.2016.08.005","article-title":"Tumor xenografts of human clear cell renal cell carcinoma but not corresponding cell lines recapitulate clinical response to sunitinib: feasibility of using biopsy samples","volume":"3","author":"Dong","year":"2017","journal-title":"Eur Urol Focus"},{"key":"2022061706341150600_bib10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1479-5876-8-14","article-title":"Comparison of three rapamycin dosing schedules in A\/J Tsc2\u00b1 mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors","volume":"8","author":"Woodrum","year":"2010","journal-title":"J Transl Med"},{"key":"2022061706341150600_bib11","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1158\/0008-5472.CAN-16-3310","article-title":"Multinuclear NMR and MRI reveal an early metabolic response to mTOR inhibition in sarcoma","volume":"77","author":"Di Gialleonardo","year":"2017","journal-title":"Cancer Res"},{"key":"2022061706341150600_bib12","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2016.10.007","article-title":"Genomic biomarkers of a randomized trial comparing first-line everolimus and sunitinib in patients with metastatic renal cell carcinoma","volume":"71","author":"Hsieh","year":"2017","journal-title":"Eur Urol"},{"key":"2022061706341150600_bib13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pnmrs.2007.03.002","article-title":"Structure-based profiling of metabolites and isotopomers by NMR","volume":"52","author":"Fan","year":"2008","journal-title":"Prog Nucl Mag Res Sp"},{"key":"2022061706341150600_bib14","doi-asserted-by":"crossref","first-page":"11147","DOI":"10.1021\/acs.analchem.6b03307","article-title":"High-throughput indirect quantitation of 13C enriched metabolites using 1H NMR","volume":"88","author":"Di Gialleonardo","year":"2016","journal-title":"Analyt Chem"},{"key":"2022061706341150600_bib15","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.copbio.2015.02.003","article-title":"A roadmap for interpreting C-13 metabolite labeling patterns from cells","volume":"34","author":"Buescher","year":"2015","journal-title":"Curr Opin Biotech"},{"key":"2022061706341150600_bib16","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1016\/j.celrep.2014.11.025","article-title":"MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies","volume":"9","author":"Baek","year":"2014","journal-title":"Cell Rep"},{"key":"2022061706341150600_bib17","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1158\/0008-5472.CAN-12-3461","article-title":"Hyperpolarized C-13-Pyruvate magnetic resonance reveals rapid lactate export in metastatic renal cell carcinomas","volume":"73","author":"Keshari","year":"2013","journal-title":"Cancer Res"},{"key":"2022061706341150600_bib18","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1091\/mbc.01-12-0584","article-title":"Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake","volume":"13","author":"Edinger","year":"2002","journal-title":"Mol Biol Cell"},{"key":"2022061706341150600_bib19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.neuroimage.2011.07.034","article-title":"Hyperpolarized C-13 MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma","volume":"59","author":"Chaumeil","year":"2012","journal-title":"Neuroimage"},{"key":"2022061706341150600_bib20","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1159\/000322545","article-title":"Initial experience with temsirolimus in 2nd-, 3rd- and 4th-line therapy for metastatic renal cell cancer: good clinical response","volume":"86","author":"Kuru","year":"2011","journal-title":"Urologia Int"},{"key":"2022061706341150600_bib21","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1158\/0008-5472.CAN-09-2251","article-title":"Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy","volume":"70","author":"Ward","year":"2010","journal-title":"Cancer Res"},{"key":"2022061706341150600_bib22","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1158\/1535-7163.MCT-15-0769","article-title":"MR studies of glioblastoma models treated with dual PI3K\/mTOR inhibitor and temozolomide:metabolic changes are associated with enhanced survival","volume":"15","author":"Radoul","year":"2016","journal-title":"Mol Cancer Thera"},{"key":"2022061706341150600_bib23","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1126\/science.1157535","article-title":"The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1","volume":"320","author":"Sancak","year":"2008","journal-title":"Science"},{"key":"2022061706341150600_bib24","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/ncb2152","article-title":"AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1","volume":"13","author":"Kim","year":"2011","journal-title":"Nat Cell Biol"},{"key":"2022061706341150600_bib25","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1039\/C3CS60124B","article-title":"Chemistry and biochemistry of C-13 hyperpolarized magnetic resonance using dynamic nuclear polarization","volume":"43","author":"Keshari","year":"2014","journal-title":"Chem Soc Rev"},{"key":"2022061706341150600_bib26","doi-asserted-by":"crossref","first-page":"18489","DOI":"10.1074\/jbc.M908096199","article-title":"Cellular release of [18F]2-fluoro-2-deoxyglucose as a function of the glucose-6-phosphatase enzyme system","volume":"275","author":"Caraco","year":"2000","journal-title":"J Biol Chem"},{"key":"2022061706341150600_bib27","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1042\/bj3620513","article-title":"The glucose-6-phosphatase system","volume":"362","author":"van Schaftingen","year":"2002","journal-title":"Biochem J"},{"key":"2022061706341150600_bib28","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1158\/0008-5472.CAN-18-0221","article-title":"Metabolic imaging of the human brain with hyperpolarized (13)C pyruvate demonstrates (13)C lactate production in brain tumor patients","volume":"78","author":"Miloushev","year":"2018","journal-title":"Cancer Res"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/79\/1\/242\/2776334\/242.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/79\/1\/242\/2776334\/242.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T19:44:48Z","timestamp":1655495088000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/79\/1\/242\/633119\/Hyperpolarized-MRI-Visualizes-Warburg-Effects-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,1]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1,2]]},"published-print":{"date-parts":[[2019,1,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-18-2231","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,1]]}}}